Utility of the Base Editing System for Introducing Drug-Resistant Gene Mutations Into Human Leukemia Cellular Models

Thao Nguyen1, Minori Tamai2, Shinichi Fujisawa3

  • 1Pediatrics, University of Yamanashi, Chuo, JPN.

Cureus
|May 9, 2025
PubMed

Insights

This study demonstrates cytidine base editing (CBE) can create leukemia cell models with specific gene mutations, aiding research into treatment resistance caused by BCR::ABL1 and TP53 mutations.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cancer Research

Background:

  • Leukemia treatment resistance is linked to diverse gene mutations.
  • Mutations in BCR::ABL1 and TP53 contribute to resistance against various therapies.
  • Developing cellular models for these mutations is crucial for understanding and overcoming resistance.

Purpose of the Study:

  • To utilize the cytidine base editing (CBE) system to engineer specific gene mutations in leukemia cell lines.
  • To evaluate the impact of introduced mutations on drug sensitivities.
  • To establish novel cellular models for studying treatment resistance in leukemia.

Main Methods:

  • Applied the CBE system to introduce the T315I mutation in BCR::ABL1.
  • Introduced the T125M mutation in TP53 using CBE in relevant leukemia cell lines.
  • Assessed drug sensitivities and characterized mutation presence in engineered cell lines.

Main Results:

  • Successfully introduced the T315I mutation in BCR::ABL1 and the T125M mutation in TP53.
  • The TP53 T125M mutation disrupted p53 protein activity and reduced sensitivity to chemotherapy and irradiation.
  • Confirmed the utility of CBE for precise gene editing in leukemia models.

Conclusions:

  • Cytidine base editing is a viable tool for creating specific nucleotide transitions in leukemia cell lines.
  • Engineered cell lines provide valuable models for investigating gene mutation-driven treatment resistance.
  • Further research using these models can inform strategies to overcome leukemia drug resistance.